In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
26 authors.
Payal P PratapDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-7170-6866 Christopher A CottrellCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-3364-3083 James QuinnCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0009-0007-8581-5418 Diane G CarnathanDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0009-0001-7073-3723 Daniel L V BaderDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7731-0494 Andy S TranDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0004-0508-6015 Chiamaka A EnemuoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Julia T NgoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Sara T RicheyDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7854-1833 Hongmei GaoDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-2468-8589 Xiaoying ShenDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-8387-3952 Kelli M GreeneDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.ORCID 0009-0008-6919-9288 Jonathan HurtadoCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0003-4145-7042 Katarzyna Kaczmarek MichaelsKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0009-0006-2393-3913 Elana Ben-AkivaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0000-0003-1085-5902 Ashley LemniosDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Mariane B MeloCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-9695-8138 Bryan BrineyCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0001-9535-2866 David MontefioriDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0003-0856-6319 Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0001-6602-2470 Darrell J IrvineCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-8637-1405 Shane CrottyCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, 92037, USA.ORCID 0000-0002-6484-6262 Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7153-3769 Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MDissecting Polyclonal Sera to Reveal Correlates of Productive Immune Responses to HIVR01AI136621 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Lars Oliver Hangartner, Andrew Barrett Ward · 2018 to 2026
$8.0MFusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primatesR01AI145629 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CROTTY, SHANE P, WARD, ANDREW BARRETT · 2019 to 2024
$4.5MNIAID NIH HHS R01 AI136621NIAID NIH HHS R01 AI145629NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011132
6 · The paper itselfAbstract
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and therefore an attractive epitope for vaccine design. Here, we describe a vaccination study in non-human primates (NHPs) where glycan deletions were made on soluble HIV Env to increase FP epitope exposure. When delivered via implantable osmotic pumps, this immunogen primed immune responses against the FP, which were then boosted with heterologous trimers resulting in a focused immune response targeting the conserved FP epitope. Although autologous immunizations did not elicit high affinity FP-targeting antibodies, the conserved FP epitope on a heterologous trimer further matured the lower affinity, FP-targeting B cells. This study suggests using epitope conservation strategies on distinct Env trimer immunogens can focus humoral responses on desired neutralizing epitopes and suppress immune-distracting antibody responses against non-neutralizing epitopes.
Identifiers
PMID39651156
PMCPMC11623688
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390